Naveglitazar (BioDeep_00000837796)
代谢物信息卡片
化学式: C25H26O6 (422.17292960000003)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: COC(CC1=CC=C(C=C1)OCCCOC2=CC=C(C=C2)OC3=CC=CC=C3)C(=O)O
InChI: InChI=1S/C25H26O6/c1-28-24(25(26)27)18-19-8-10-20(11-9-19)29-16-5-17-30-21-12-14-23(15-13-21)31-22-6-3-2-4-7-22/h2-4,6-15,24H,5,16-18H2,1H3,(H,26,27)/t24-/m0/s1
描述信息
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C154291 - Peroxisome Proliferator-Activated Receptor Agonist
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:188591
- KEGGdrug: D08949
- PubChem: 9888484
- DrugBank: DB12662
- ChEMBL: CHEMBL181954
- CAS: 476436-68-7
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Yoshihiro Shibata, Katsuji Kagechika, Mitsuhiro Yamaguchi, Hideo Kubo, Hiroyuki Usui. Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1).
Bioorganic & medicinal chemistry letters.
2012 Dec; 22(23):7075-9. doi:
10.1016/j.bmcl.2012.09.092. [PMID: 23084275] - Preeti Ahlawat, Nuggehally R Srinivas. Allometric prediction of the human pharmacokinetic parameters for naveglitazar.
European journal of drug metabolism and pharmacokinetics.
2008 Jul; 33(3):187-90. doi:
10.1007/bf03191117. [PMID: 19007045] - Gerald G Long, Vincent L Reynolds, Alric Lopez-Martinez, Thomas E Ryan, Sandy L White, Sandra R Eldridge. Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event.
Toxicologic pathology.
2008 Feb; 36(2):218-31. doi:
10.1177/0192623307311757. [PMID: 18474944] - Holly J Clarke, Francine Gregoire, Fang Ma, Robert Martin, Spring Zhao, Brian E Lavan. Cross-Species Differential Plasma Protein Binding of MBX-102/JNJ39659100: A Novel PPAR-gamma Agonist.
PPAR research.
2008; 2008(?):465715. doi:
10.1155/2008/465715. [PMID: 18815616] - Martin B Oleksiewicz, Jennifer Southgate, Lars Iversen, Frederikke L Egerod. Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists.
PPAR research.
2008; 2008(?):103167. doi:
10.1155/2008/103167. [PMID: 19197366] - Ping Yi, Chad E Hadden, William F Annes, David A Jackson, Barry C Peterson, Todd A Gillespie, Jason T Johnson. The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats, and monkeys.
Drug metabolism and disposition: the biological fate of chemicals.
2007 Jan; 35(1):51-61. doi:
10.1124/dmd.106.012328. [PMID: 17012539] - José A Martín, Dawn A Brooks, Lourdes Prieto, Rosario González, Alicia Torrado, Isabel Rojo, Beatriz López de Uralde, Carlos Lamas, Rafael Ferritto, María Dolores Martín-Ortega, Javier Agejas, Francisco Parra, John R Rizzo, Gary A Rhodes, Roger L Robey, Charles A Alt, Samuel R Wendel, Tony Y Zhang, Anne Reifel-Miller, Chahrzad Montrose-Rafizadeh, Joseph T Brozinick, Eric Hawkins, Elizabeth A Misener, Daniel A Briere, Robert Ardecky, James D Fraser, Alan M Warshawsky. 2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents.
Bioorganic & medicinal chemistry letters.
2005 Jan; 15(1):51-5. doi:
10.1016/j.bmcl.2004.10.042. [PMID: 15582409]